Latest News and Press Releases

- TransCon TLR7/8 Agonist continued to be well-tolerated and demonstrated early signs of clinical activity as monotherapy or in combination with pembrolizumab - Abstract for dose-escalation topline...

-  Durability of response to TransCon PTH therapy through Week 110 demonstrated by continued normalization of serum calcium and 93% achieving independence from conventional therapy -  Participants...

COPENHAGEN, Denmark, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in three upcoming investor conferences in...

•   TransCon PTH could, if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an area of major unmet medical need for the estimated...

—  U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022 —  SKYTROFA revenue continued...

COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022,...

–  Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 –  Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label...

-  Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology -  Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial...

-   VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks...

Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidismTransCon PTH U.S. FDA regulatory...